MPG.eBooks - Description: CADTH Canadian Drug Expert Committee recommendation: Nusinersen (Spinraza -- Biogen Canada Inc.)

Read Now

The CADTH Canadian Drug Expert Committee (CDEC) recommends that nusinersen be reimbursed for the treatment of 5q Spinal Muscular Atrophy (SMA)

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, December 2017
Edition:	Version 1.0
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Canada Oligonucleotides / Therapeutic Use Muscular Atrophy, Spinal / Drug Therapy Cost-benefit Analysis Oligonucleotides / Economics
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK533397
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that nusinersen be reimbursed for the treatment of 5q Spinal Muscular Atrophy (SMA)
Item Description:	"Final."
Physical Description:	1 PDF file (9 pages)